Bulletin
Investor Alert

Jasper Therapeutics Inc.

NAS: JSPR

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Jasper Therapeutics Inc.

Market closed

 --Quotes are delayed by 20 min

Jun 9, 2023, 4:00 p.m.

JSPR
/zigman2/quotes/206872721/composite

$

1.57

Change

-0.02 -1.26%

Volume

Volume 99,839

Quotes are delayed by 20 min

/zigman2/quotes/206872721/composite

Previous close

$ 1.59

$ 1.57

Change

-0.02 -1.26%

Day low

Day high

$1.56

$1.63

Open

52 week low

52 week high

$0.39

$3.80

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Jasper Therapeutics Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 202020212022 5-year trend
Sales/Revenue -----
Cost of Goods Sold (COGS) incl. D&A --21,000566,0001.31M
COGS excluding D&A -----
Depreciation & Amortization Expense --21,000566,0001.31M
Depreciation --21,000566,0001.31M
Amortization of Intangibles -----
Gross Income --(21,000)(566,000)(1.31M)
202020212022 5-year trend
SG&A Expense --20.96M37.36M51.72M
Research & Development --16.18M26.52M36.46M
Other SG&A --4.78M10.85M15.26M
Other Operating Expense -----
Unusual Expense --10.88M(6.28M)(12.93M)
EBIT after Unusual Expense --(10.88M)(31.65M)(40.11M)
Non Operating Income/Expense --(111,000)(80,000)586,000
Non-Operating Interest Income -----
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income --(31.97M)(31.73M)(39.52M)
Income Tax --(298,000)(1.1M)(1.84M)
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits --298,0001.1M1.84M
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income --(31.67M)(30.64M)(37.69M)
Minority Interest Expense -----
Net Income --(31.67M)(30.64M)(37.69M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries --(31.67M)(30.64M)(37.69M)
Preferred Dividends -----
Net Income Available to Common --(31.67M)(30.64M)(37.69M)
EPS (Basic) --(11.43)(2.69)(1.03)
Basic Shares Outstanding --2.77M11.39M36.48M
EPS (Diluted) --(11.43)(2.69)(1.03)
Diluted Shares Outstanding --2.77M11.39M36.48M
EBITDA --(20.96M)(37.36M)(51.72M)
Copyright 2023 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.